Enveric Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Enveric Biosciences, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Enveric Biosciences, Inc..
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Enveric Biosciences, Inc.
1.47
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.
+2.09%
shares held · 7 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Sio | $248,400 | 33.99% | new |
| Ikarian Capital | $138,003 | 18.88% | new |
| AdvisorShares | $48,875 | 6.69% | +108.65% |
| Renaissance Technologies | $44,240 | 6.05% | new |
| Armistice Capital | $44,160 | 6.04% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Sio | $248,400 | 33.99% | new |
| Ikarian Capital | $138,003 | 18.88% | new |
| AdvisorShares | $48,875 | 6.69% | +108.65% |
| Renaissance Technologies | $44,240 | 6.05% | new |
| Armistice Capital | $44,160 | 6.04% | new |